Hanmi Pharm Reveals Three Items Including Lab Discovery Innovative Drug Clinical Trials at European Conference

Hanmi Pharmaceutical participated in the European Society for Clinical Nutrition and Metabolism held in Vienna, Austria.

[Asia Economy Reporter Kwanju Lee] Hanmi Pharmaceutical announced on the 15th that it revealed three clinical and preclinical studies of innovative new drugs based on the Labscovery platform at the European Society for Clinical Nutrition and Metabolism (ESPEN) held recently in Vienna, Austria.

Hanmi Pharmaceutical first presented detailed information on the global Phase 2 clinical trial design, subject selection criteria, clinical duration, and target endpoints of 'Labs GLP-2 analog (HM15912),' an innovative new drug for short bowel syndrome being developed as a once-monthly formulation, in a poster presentation.

HM15912 is an innovative new drug applying Hanmi Pharmaceutical's sustained-release platform technology, Labscovery, to a GLP-2 analog. Based on improved in vivo durability of GLP-2 and excellent villus cell growth-promoting effects, it is being developed as the world's first once-monthly formulation. Recently, it entered a global and domestic Phase 2 monotherapy clinical trial targeting patients with short bowel syndrome.

In addition, two preclinical studies confirming the potential for developing an inflammatory bowel disease treatment combining HM15912 and efpeglenatide were also presented. Efpeglenatide, a GLP-1 receptor agonist diabetes treatment, is a biopharmaceutical that can be administered once weekly or up to once monthly, and has demonstrated efficacy in reducing blood glucose and body weight in patients with type 2 diabetes, as well as reducing the incidence of major adverse cardiovascular events (MACE) and kidney disease.

In preclinical studies, HM15912 and efpeglenatide each showed efficacy in suppressing inflammatory bowel disease markers and increasing small intestine weight, with additional improvements observed when combined. In particular, in combination studies using rodent models of Crohn's disease and ulcerative colitis, the combination further alleviated intestinal inflammation and effectively prevented intestinal damage, the company reported.

A Hanmi Pharmaceutical official stated, “We confirmed that the combination of HM15912 and efpeglenatide can develop new treatment options for inflammatory bowel disease based on their intestinal growth-promoting and anti-inflammatory effects,” adding, “We will do our best to develop innovative treatments that can significantly improve patients' quality of life based on the research presented this time.”

This content was produced with the assistance of AI translation services.